Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4+and CD8+T cells. In First Nations participants, RBD IgG ...
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377:eabq1841. Article CAS PubMed Google Scholar Gao B, He L, Bao Y, Chen Y, Lu G, Zhang Y, et al. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies ...
high magnitude T cell responses are generated after two vaccine doses, with the majority of the T cell response directed against epitopes that are conserved between the prototype isolate B and the VOC. Vaccination is required to generate high potency immune responses to protect against these and ...
The ability of a third dose of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine to stimulate immune responses against subvariants, including Omicron BA.1, has not been assessed in New Zealand populations. Unlike many overseas populations, New Zealanders were largely infection naïve at the time...
Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Canton
Sera were collected from 185 adults aged≥70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in>94% seropositivity after 3 weeks in nave individuals using the Roche Spike antibody assay, while two doses produced very high...
Replicating RNA expresses a greater amount of protein, and also triggers a virus-sensing stress response that encourages other immune activation. In the case of the COVID-19 vaccine candidate, the RNA enters cells and instructs them to produce proteins that teach the body to recognize coronavirus...
Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection Article Open access 11 June 2024 Introduction To date, our knowledge of children’s immune response to infection with severe acute respiratory syndrome coronavirus type 2 (...
The T cell response of critical COVID-19 patients is robust and comparable or even superior to non-critical patients. Virus clearance and COVID-19 survival are not associated with either SARS-CoV-2 T cell kinetics or magnitude of T cell responses, respectively. Thus, our data do not ...
During the COVID-19 pandemic, the mRNA vaccine technology was widely applied, demonstrating its effectiveness and reliability with a swift response, short production cycle, and excellent safety profile (Fang et al., 2022; Pardi et al., 2018). Development of mRNA vaccines targeting MPV is the ...